Biotechnology - Bristol-Myers Squibb

Filter

Current filters:

Bristol-Myers Squibb

Popular Filters

1 to 25 of 50 results

NSCLC treatment market set to grow to more than $7.9 billion by 2020

NSCLC treatment market set to grow to more than $7.9 billion by 2020

09-09-2014

The global non-small cell lung cancer treatment market value will increase from $5.1 billion in 2013…

BiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGilotrifGlobalMarkets & MarketingnecitumumabnivolumabOncologyYervoy

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

Bristol-Myers Squibb form company with Allied Minds for research and preclinical development

Bristol-Myers Squibb form company with Allied Minds for research and preclinical development

04-08-2014

US drug major Bristol-Myers Squibb and science and technology development company Allied Minds are to…

BiotechnologyBristol-Myers SquibbDrug discoveryResearchUSA

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment

20-06-2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

EULAR: High rates of DAS-defined remission with Bristol-Myers’ Orencia in early RA

12-06-2014

US drug major Bristol-Myers Squibb has released new data from a Phase IIIb RA trial showing that the…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbOrenciaResearch

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

Bristol-Myers Squibb extends research accord with Biocon unit Syngene

05-06-2014

US pharma major Bristol-Myers Squibb and Syngene International, India’s largest contract research organization,…

BioconBiotechnologyBristol-Myers SquibbIndiaResearchSyngene

Bristol-Myers and Celldex to evaluate nivolumab and varlilumab combo

14-05-2014

US drug major Bristol-Myers Squibb and biotech firm Celldex Therapeutics have entered into a clinical…

BiotechnologyBristol-Myers SquibbCelldex TherapeuticsnivolumabOncologyResearchvarlilumab

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

Bristol-Myers acquires iPierian for $175 million upfront, plus $550 possible milestones

30-04-2014

US pharma major Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused…

BiotechnologyBristol-Myers SquibbiPierianIPN007Mergers & AcquisitionsNeurological

Bristol-Myers Squibb and Samsung BioLogics expand manufacturing deal

23-04-2014

US drug major Bristol-Myers Squibb and South Korea’s Samsung BioLogics revealed that they will increase…

Asia-PacificBiotechnologyBristol-Myers SquibbProductionSamsung BioLogics

Modest growth seen for MAbs market for colorectal cancer, as late-stage pipeline is weak

14-12-2013

The market value for monoclonal antibodies in colorectal cancer treatment will experience a moderate…

AvastinBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck KGaAOncologyResearchRocheTakeda PharmaceuticalsVectibix

Eli Lilly's investigational sNSCLC drug meets Ph III endpoint

14-08-2013

US drug major Eli Lilly's (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company…

BiotechnologyBristol-Myers SquibbEli LillynecitumumabOncologyPharmaceuticalResearch

Bristol-Myers partners with South Korean firm on biopharma production

29-07-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a 10-year agreement under which Samsung…

Asia-PacificBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalProductionSamsung BioLogics

New EULAR recommendations address use of synthetic and biological DMARDs

05-07-2013

The European League Against Rheumatism (EULAR) has this week released updated recommendations for the…

ActemraBiotechnologyBristol-Myers SquibbEuropeHealthcareMabTheraOrenciaPfizerPharmaceuticalRegulationRocheXeljanz

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

1 to 25 of 50 results

Back to top